Cargando…

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England

PURPOSE: Inhaled triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who have poorly controlled symptoms and to reduce the risk of exacerbations. This study assessed the clinical characteristics of new users of single- and multiple-inhaler triple therapy (SIT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rothnie, Kieran J, Joksaite, Sandra, Sansbury, Leah B, Compton, Chris, Di Boscio, Valentina, Ismaila, Afisi S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234193/ https://www.ncbi.nlm.nih.gov/pubmed/35769225 http://dx.doi.org/10.2147/COPD.S338436

Ejemplares similares

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England
por: Sansbury, Leah B, et al.
Publicado: (2022)

Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice
por: Sansbury, Leah B, et al.
Publicado: (2021)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK
por: Rothnie, Kieran J, et al.
Publicado: (2023)

Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting
por: Halpin, David M G, et al.
Publicado: (2022)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
por: Zhang, Shiyuan, et al.
Publicado: (2020)

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
por: Paly, Victoria Federico, et al.
Publicado: (2022)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2022)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
por: Sicras Mainar, Antoni, et al.
Publicado: (2019)

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
por: Ismaila, Afisi S., et al.
Publicado: (2023)

SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study
por: Ismaila, AS, et al.
Publicado: (2022)

Current appraisal of single inhaler triple therapy in COPD
por: Lipworth, Brian, et al.
Publicado: (2018)

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective
por: Schroeder, Melanie, et al.
Publicado: (2020)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
por: Resta, Emanuela, et al.
Publicado: (2022)

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial
por: Ismaila, Afisi S., et al.
Publicado: (2017)

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
por: Iheanacho, Ike, et al.
Publicado: (2020)

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
por: Neches García, Victoria, et al.
Publicado: (2022)

Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
por: Mannino, David, et al.
Publicado: (2022)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
por: Ferguson, Gary T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c94238ftrk6o53g0kf4k075f52